Ax-003/Arimidex (Anastrozole) in the adjuvant therapy of early breast cancer - Ax-003
Study identifier:Ax-003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Postmenopausal women with early hormone-receptor positive breast cancer/no metastasis
Medical condition
Breast Cancer
Phase
-
Healthy volunteers
No
Study drug
Anastrozole
Sex
Female
Actual Enrollment
1600
Study type
Observational
Age
N/A
Date
Study Start Date: 01 May 2005
Primary Completion Date: -
Study Completion Date: 01 Mar 2007
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Mar 2008 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 all patients treated with Anastrozole | - |
Contacts
Investigators
Principal Investigator
H Brasch
AstraZeneca Germany
